On 15 June 2026, a Nature Genetics study led by the Wellcome Sanger Institute, Cambridge University Hospitals NHS Foundation Trust and Open Targets mapped over 1.1 million gut cells from Crohn’s patients and controls and released the IBDverse single‑cell resource.
Key findings
- Scale of profiling: Single‑cell RNA sequencing of 1,185,000+ gut cells from 111 Crohn’s patients and 232 healthy individuals.
- Molecular scar: Gut stem cells retain persistent activation of immune‑signalling genes after visible inflammation subsides.
- Inflammatory macrophages: A macrophage subset with high ITGA4 expression drives inflammation via the JAK/STAT pathway.
Methodology & resource
- Technique: Single‑cell RNA sequencing enabling cell‑type–specific transcriptional maps.
- IBDverse: Open online atlas containing data from ~1.18 million small‑intestine cells for researchers and drug target validation.
Clinical & genetic insights
- Therapeutic link: JAK/STAT involvement aligns with existing JAK inhibitor drugs used in inflammatory bowel disease.
- Anatomical focus: Crohn’s disease commonly affects the terminal ileum but can involve multiple gut sites.
- Outcomes data: Approximately 15% of patients require surgery within five years due to non‑response to immune‑targeted therapies.
- Genetic marker: HLA‑DRB1*01:03 associated with more severe Crohn’s and ulcerative colitis phenotypes.
IASPOINT Booster Facts
- JAK/STAT pathway: Cytokine receptor signalling cascade; JAK inhibitors block JAK kinases to reduce downstream STAT‑mediated transcription.
- ITGA4: Encodes α4 integrin; targetable in gut inflammation (therapeutic relevance to cell trafficking and adhesion).
- Single‑cell advantage: Resolves heterogeneity missed by bulk RNA‑seq; identifies rare pathogenic cell populations.